In late August, when Dynavax Technologies Corp. heard that the FDA nixed an advisory panel to consider the BLA for HBV vaccine Heplisav-B, a few holdouts speculated that the news might bode well – it could mean that regulators had decided the panel wasn’t necessary and only a few details remained to be worked out before approval.